Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342716 | 0.87 | GPR119 (0.66) | GPR119USP30PDE4BALDH1A1CHEK2 | |
| SCHEMBL10190106 | 0.86 | USP30 (0.55) | GPR119USP30PDE4BALDH1A1CHEK2 | |
| SCHEMBL24793305 | 0.85 | USP30 (0.49) | GPR119USP30NR1H2NAMPTPDE4B | |
| SCHEMBL28670992 | 0.85 | USP30 (0.53) | GPR119USP30NR1H2NAMPTALDH1A1 | |
| SCHEMBL6182215 | 0.85 | USP30 (0.53) | GPR119USP30NR1H2ALDH1A1CHEK2 | |
| SCHEMBL12788093 | 0.85 | USP30 (0.53) | GPR119USP30NR1H2ALDH1A1CHEK2 | |
| SCHEMBL321227 | 0.84 | KCNH2 (0.54) | GPR119USP30 | |
| SCHEMBL3343250 | 0.83 | USP30 (0.52) | GPR119USP30NR1H2ALDH1A1CHEK2 | |
| SCHEMBL16434828 | 0.83 | USP30 (0.52) | GPR119USP30ALDH1A1 | |
| SCHEMBL14862587 | 0.83 | USP30 (0.52) | GPR119USP30NR1H2NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | GPR119 4354/4885USP30 740/4885NR1H2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.